Skip to content


Celebrating Over 80 Years Of Service!

The American Academy of Otolaryngic Allergy (AAOA) represents over 2,700 Board-certified otolaryngologists and health care providers. Otolaryngology, frequently referred to as Ear, Nose, and Throat (ENT), uniquely combines medical and surgical expertise to care for patients with a variety of conditions affecting the ears, nose, and throat, as well as commonly related conditions. AAOA members devote part of their practice to the diagnosis and treatment of allergic disease. The AAOA actively supports its membership through education, research, and advocacy in the care of allergic patients.

"Advance the comprehensive management of allergy and inflammatory disease in Otolaryngology-Head and Neck Surgery through training, education, and advocacy."

AAOA Member Benefits

  • Up to 60% discount for CME programs and free Annual Meeting. All AAOA’s CME programs meet ABOTOHNS Continuing Certification.
  • AAOA US ENT Affinity program, where AAOA members can gain savings on antigen, allergy supplies, and any of the other 5 service lines US ENT offers. For more email
  • Tools and resources to comply with US General Chapter 797 and practice management tools.
  • Advocacy support.
  • And much more! Learn More


As part of our on-going member support, we are introducing a new website feature to help with common practice management challenges. We welcome your input with questions or challenges you would like to address. Read More


Video On USP General Chapter

On November 1, 2023, the new chapter of USP General Chapter <797> was implemented. AAOA has…

Read more

USP General Chapter Resources

November 1, 2023 is the implementation date for the new chapter. AAOA has resources and…

Read more

United Healthcare Home Immunotherapy Policy Change

United Healthcare has recently announced a policy change. Effective January 1, 2023, UHC will no longer…

Read more

Upcoming Dates

04/01/24: Fellow Exam Application Deadline
Learn more

06/01/24: Research Grant Cycle
Learn more

08/02/24: Scientific Abstract Submission Deadline
Learn more

12/01/24: Research Grant Cycle
Learn more


AAOA Basic Course

Join us from July 25-27 at the hybrid 2024 AAOA Basic Course. As a hybrid course, we are excited to offer both live in-person and virtual participation. The course content will be accessible for over 90 days to help you maximize value. Register Today 


For information about Resident membership, opportunities, DosedDaily, research grants, and other resources. Learn More


Available Now


IFAR Impact Factor: 2.454

IFAR Featured Content: COVID-19 - Free Access
Endonasal instrumentation and aerosolization risk in the era of COVID‐19: simulation, literature review, and proposed mitigation strategies . Read More

Changes in Managing Practices

Working together with AAOA staff, volunteer leadership and members will enable us to have a positive impact on our members’ practices.

Read More

Live and Online CME

2024 AAOA Basic Course in Allergy & Immunology - Hybrid
July 25-27, 2024
The Diplomat, Hollywood, Florida
Learn More and Register

2024 AAOA Annual Meeting - Hybrid
November 8-10, 2024
Four Seasons Hotel Las Vegas
Learn More and Register 

2025 AAOA Advanced Course in Allergy & Immunology - Hybrid
March 27-29, 2025
The Hythe, Vail, CO
Book Your Room

USP 797 Online Module
Learn More and Register

AAOA Educational Stacks
Next Release October 1, 2024

News and Updates

Value of AAOA Membership 2024

Join Drs. Puchalski, Baker and Wilson as they discuss the value of AAOA Membership.…

Read more

CEO Update, March 2024

March is such an optimistic month. (Although some may wonder this year with the extension of…

Read more
College Allergy Symptoms Treatment Back to Shcool


AAOA Practice Resource Tool Kit

The American Academy of Otolaryngic Allergy (AAOA) Practice Resource Tool Kit is intended as a guide to help AAOA members integrate allergy into their otolaryngology practice and to continually improve on this integration as new information, regulations, and resources become available.

Read More


AAOA has launched a Partner Resource Center to bring you partner resources that can assist your practice and patient care.

Visit the New Center>


American Elm Shortage

American Elm is dying from Dutch Elm Disease. This may explain the concentrate shortage many practices and antigen suppliers are experiencing.

To help, there are many other elm species that are more or less resistant to this fungal disease and still cause allergic symptoms.  There is little cross-reactivity outside the elm family, so the best bet to overcome the shortage and help your patients is to substitute another elm species for allergen testing and immunotherapy.

Several Elm species are commercially available, including Slippery Elm and Chinese Elm.  Other options to consider include Mulberry, Hemp, and Hops — all closely related.  None of these substitutes are going to be exact matches, either for antigen profile or for potency.  Additionally, you can discuss further with the pharmacist at your Antigen source company to identify the most readily available cross-reactive option.  

Whichever you choose to use to replace American Elm will require mandatory vial testing for each patient who is switched to the new antigen. Best option to consider when replacing American Elm for Chinese Elm on your mixing board is to cut back one 5-fold dilution (5-fold) and then do a vial check.  Retesting is not necessary.  

For those with patients on monthly maintenance injections, you may need to re-escalate. With the recommendation of  a 1:5 dilution with the addition of the new Elm product, that implies the need for re-escalating back to the maintenance dose. If the patient is on monthly injections, and you use the standard AAOA escalation, it would take nearly 2 years to get back up to full maintenance dose or the patient will need to go back to weekly injections for five months until get back to full maintenance. You may want to consider a more rapid weekly re-escalation for a patient already on monthly maintenance, such as 0.1, 0.2, 0.3, 0.4, and 0.5 , which would cut down on the time to get back to full maintenance. This should be reasonably safe due to the cross-reactivity. 

Back To Top